Altimmune’s (ALT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Altimmune (NASDAQ:ALT) in a research report sent to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock.

ALT has been the topic of a number of other research reports. B. Riley reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. UBS Group began coverage on Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target for the company. Finally, Evercore ISI raised Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Altimmune Price Performance

Altimmune stock opened at $7.61 on Thursday. The business has a 50 day simple moving average of $7.02 and a 200-day simple moving average of $6.91. Altimmune has a 12 month low of $2.34 and a 12 month high of $14.84. The stock has a market capitalization of $541.22 million, a PE ratio of -4.91 and a beta of 0.09.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the previous year, the company posted ($0.39) EPS. As a group, equities research analysts anticipate that Altimmune will post -1.36 EPS for the current year.

Institutional Trading of Altimmune

Several large investors have recently bought and sold shares of ALT. Price T Rowe Associates Inc. MD grew its position in shares of Altimmune by 13.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock valued at $156,000 after purchasing an additional 1,821 shares during the last quarter. Creative Planning grew its holdings in Altimmune by 20.5% during the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after buying an additional 3,132 shares during the last quarter. CANADA LIFE ASSURANCE Co purchased a new position in Altimmune during the first quarter worth $44,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after acquiring an additional 4,772 shares during the last quarter. Finally, Larson Financial Group LLC acquired a new position in shares of Altimmune in the third quarter worth $31,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.